Hi @Bazsa,
yep. I don't know how FDA reviewers can sleep after letting RUXOLITINIB's clinical evidence through without questioning these numbers, either effectively at the time or since.
It's even more 'graphic' IMO when depicted graphically, as extracted from the authors' Supplementary Materials below (link here):
and
They mixed it with steroids & even then that hazard ratio of ~91% indicates there was barely a <10% relative occurrence risk difference between the 2 sets of datapoints that they took out of the randomised trial.
I'd be keen to hear Dr Vinay Prasad's view of these numbers. He's had a thing or two to say about the importance of demonstrated OS to the FDA as he sees it going forward.
We'll see.
Cheers
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast and FDA Align on Key Items for Revascor BLA
MSB
mesoblast limited
Add to My Watchlist
2.88%
!
$2.36

Ann: Mesoblast and FDA Align on Key Items for Revascor BLA, page-129
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.36 |
Change
-0.070(2.88%) |
Mkt cap ! $3.020B |
Open | High | Low | Value | Volume |
$2.40 | $2.42 | $2.34 | $8.337M | 3.518M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6198 | $2.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.37 | 5376 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6198 | 2.360 |
1 | 10000 | 2.350 |
2 | 16000 | 2.340 |
13 | 66773 | 2.330 |
5 | 55145 | 2.320 |
Price($) | Vol. | No. |
---|---|---|
2.370 | 5376 | 2 |
2.380 | 33755 | 1 |
2.390 | 23685 | 3 |
2.400 | 25500 | 4 |
2.410 | 83737 | 6 |
Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |